Vasomotor Symptoms Market Expected to Grow Through 2036, Driven by Novel Non-Hormonal Therapies and Rising Menopausal Healthcare Awareness | DelveInsight

The Vasomotor Symptoms (VMS) market is anticipated to witness substantial growth across the Seven Major Markets (7MM) and the Rest of the World (ROW) during the forecast period (2026-2036). Market expansion is expected to be fueled by the growing menopausal population, increasing awareness of women's health, improved diagnosis, the launch of innovative non-hormonal therapies, and continued investments in women's healthcare. The emergence of novel neurokinin receptor antagonists and other targeted therapies is expected to significantly reshape the treatment landscape for vasomotor symptoms associated with menopause.

DelveInsight's "Vasomotor Symptoms (Hot Flashes/Night Sweats) Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive analysis of disease epidemiology, current treatment practices, marketed therapies, emerging pipeline products, market trends, pricing analysis, therapy uptake, reimbursement landscape, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and the Rest of the World (ROW). The report also evaluates patient burden, competitive intelligence, and future commercial opportunities expected to influence the Vasomotor Symptoms market over the coming decade.
The report further assesses historical and forecasted market performance, emerging treatment innovations, key opinion leader perspectives, unmet needs, and evolving healthcare policies that are expected to shape the future of menopause-related vasomotor symptom management.

To know more about the Vasomotor Symptoms market, epidemiology, and forecast, Click here:
https://www.delveinsight.com/sample-request/vasomotor-symptoms-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Vasomotor Symptoms Market Report

• The Vasomotor Symptoms market across the 7MM + ROW is projected to grow steadily during the forecast period (2026-2036), driven by improved diagnosis, treatment advancements, an aging female population, increasing awareness, the introduction of emerging therapies, and rising healthcare expenditure.
• According to DelveInsight's analysis, the global Vasomotor Symptoms market is expected to increase from approximately USD 6.8 billion in 2020 to nearly USD 12.4 billion by 2036 across the 7MM and ROW.
• Vasomotor symptoms, commonly manifested as hot flashes and night sweats, affect nearly 60% of women aged 40-64 years worldwide, making them among the most common and burdensome symptoms associated with menopause.
• In November 2025, Bayer received US FDA approval for LYNKUET (elinzanetant) 60 mg capsules for the treatment of moderate-to-severe menopausal vasomotor symptoms, further expanding the available non-hormonal treatment options.
• In February 2026, Astellas Pharma announced positive topline results from the Phase III STARLIGHT 2 trial in Japan evaluating VEOZAH (fezolinetant) for menopausal vasomotor symptoms, supporting continued global expansion of the therapy.
• The current treatment landscape includes lifestyle modifications, hormone replacement therapy (HRT), non-prescription remedies, and non-hormonal prescription therapies, while several novel therapies remain under clinical development.
• Promising investigational therapies, including Cendifensine (NOE-115) by Noema Pharma and Asimadoline by Tioga Pharmaceuticals, are expected to strengthen the future treatment landscape by offering additional non-hormonal therapeutic options.

Key Factors Driving the Vasomotor Symptoms Market

Increasing Menopausal Population and Aging Demographics
Growing life expectancy and an expanding population of postmenopausal women continue to increase the prevalence of vasomotor symptoms worldwide. As women spend a larger portion of their lives in the postmenopausal stage, demand for effective symptom management continues to rise across developed and emerging healthcare markets.

Growing Adoption of Non-Hormonal Therapies
While hormone replacement therapy remains an effective treatment for many women, concerns regarding long-term safety have accelerated the development and adoption of innovative non-hormonal therapies. Recently approved neurokinin receptor antagonists and emerging pipeline candidates are expanding treatment options for women who cannot or prefer not to receive hormone therapy.
Strong Clinical Pipeline

The clinical pipeline continues to expand with novel therapies targeting different biological mechanisms involved in thermoregulation. Investigational candidates such as Cendifensine (NOE-115), Asimadoline, and GenSci074 demonstrate the industry's growing commitment to developing safer and more effective therapies for menopausal vasomotor symptoms.

Increasing Awareness of Women's Health
Rising awareness of menopause management, improved physician education, expanding women's health initiatives, and better healthcare accessibility are contributing to earlier diagnosis and greater treatment uptake. Growing acceptance of menopause as an important healthcare priority is expected to further support market growth throughout the forecast period.

Vasomotor Symptoms Market Analysis

• Vasomotor symptoms remain among the most common manifestations of menopause and significantly affect quality of life through recurrent episodes of hot flashes, night sweats, sleep disturbances, mood changes, and impaired daily functioning. Although hormone replacement therapy has historically been considered the standard treatment, safety concerns associated with long-term hormone use have accelerated interest in non-hormonal therapeutic alternatives.
• Recent regulatory approvals of innovative therapies such as VEOZAH (fezolinetant) and LYNKUET (elinzanetant) have introduced a new era of targeted, non-hormonal treatment options. At the same time, investigational therapies including Cendifensine (NOE-115) and Asimadoline continue to advance through clinical development, highlighting the industry's focus on addressing persistent unmet needs among women who are ineligible for or unwilling to use hormone therapy.
• According to DelveInsight, continued improvements in diagnosis, greater awareness of menopause-related health concerns, increasing healthcare expenditure, favorable demographic trends, expanding access to innovative therapies, and ongoing pharmaceutical innovation are expected to drive sustained market growth across the 7MM and ROW through 2036. As the therapeutic landscape evolves, novel targeted therapies are anticipated to improve clinical outcomes while expanding commercial opportunities within the global Vasomotor Symptoms market.

Get a Free sample for the Vasomotor Symptoms Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/vasomotor-symptoms-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Vasomotor Symptoms Competitive Landscape

• The Vasomotor Symptoms (VMS) treatment landscape has evolved considerably in recent years with the introduction of innovative non-hormonal therapies that address menopausal hot flashes and night sweats without the risks associated with hormone replacement therapy (HRT). While hormone-based therapies continue to play an important role in symptom management, the approval of neurokinin receptor antagonists and the advancement of several pipeline candidates are transforming the competitive environment. The market is characterized by established pharmaceutical companies with approved therapies alongside emerging biotechnology firms developing next-generation non-hormonal treatments.
• Currently marketed therapies include DUAVEE (bazedoxifene acetate/conjugated estrogens) from Pfizer, VEOZAH (fezolinetant) from Astellas Pharma, and LYNKUET (elinzanetant) from Bayer. Meanwhile, investigational therapies such as Cendifensine (NOE-115) by Noema Pharma, Asimadoline by Tioga Pharmaceuticals, and GenSci074 by Changchun GeneScience Pharmaceuticals are expected to further diversify treatment options during the forecast period.

Emerging Therapies Driving the Vasomotor Symptoms Market

Cendifensine (NOE-115): Noema Pharma
Cendifensine (NOE-115) is an investigational broad-spectrum monoamine modulator being developed by Noema Pharma as a once-daily oral, non-hormonal therapy for menopausal vasomotor symptoms. The therapy is currently undergoing Phase IIa clinical evaluation and is designed to alleviate both vasomotor symptoms and associated menopausal manifestations through monoaminergic reuptake modulation.
In November 2025, Noema Pharma reported positive Phase IIa results from an open-label study, demonstrating significant reductions in both the frequency and severity of moderate-to-severe vasomotor symptoms compared with baseline, supporting continued clinical development.

Asimadoline: Tioga Pharmaceuticals
Asimadoline is a peripherally restricted kappa-opioid receptor (KOR) agonist being developed by Tioga Pharmaceuticals as a novel non-hormonal therapy for vasomotor symptoms associated with menopause. The therapy selectively targets peripheral sensory and autonomic pathways and is believed to regulate thermoregulatory signaling by suppressing KNDy neuron-mediated pathways involved in the pathophysiology of hot flashes.
In June 2025, Tioga initiated enrollment in a Phase IIa clinical trial evaluating Asimadoline in women experiencing menopausal vasomotor symptoms, with clinical data anticipated in 2026.

GenSci074: Changchun GeneScience Pharmaceuticals
GenSci074 is an investigational neurokinin-3 receptor (NK3R) antagonist being developed by Changchun GeneScience Pharmaceuticals for the treatment of moderate-to-severe menopausal vasomotor symptoms. According to the report, the clinical development of GenSci074 is currently being conducted outside the 7MM.

In January 2026, the company announced that GenSci074 successfully met all primary endpoints in a China Phase II clinical trial, demonstrating statistically significant reductions in the frequency and severity of hot flashes while maintaining a safety profile comparable to placebo. Based on these findings, the company plans to initiate a global Phase III multi-regional clinical trial during Q2 2026.

Recent Developments in the Vasomotor Symptoms Market

• In February 2026, Astellas Pharma reported positive topline results from the Phase III STARLIGHT 2 trial in Japan evaluating VEOZAH (fezolinetant) for menopausal vasomotor symptoms.
• In November 2025, the US FDA approved Bayer's LYNKUET (elinzanetant) 60 mg capsules for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
• In November 2025, Noema Pharma announced positive Phase IIa clinical results for Cendifensine (NOE-115), demonstrating meaningful reductions in both the frequency and severity of vasomotor symptoms.
• In June 2025, Tioga Pharmaceuticals initiated enrollment in a Phase IIa clinical trial evaluating Asimadoline for menopausal vasomotor symptoms, with study results expected in 2026.
• In January 2026, Changchun GeneScience Pharmaceuticals announced positive Phase II results for GenSci074 in China and confirmed plans to initiate a global Phase III clinical trial in the second quarter of 2026.

What are Vasomotor Symptoms?

Vasomotor Symptoms (VMS) are episodes of intense heat sensation accompanied by hot flashes, night sweats, flushing, excessive perspiration, heart palpitations, and fluctuations in blood pressure. They primarily occur around the head, neck, chest, and upper back and are widely recognized as the hallmark symptoms of menopause. Vasomotor symptoms result from hormonal changes that disrupt the body's thermoregulatory mechanisms and can substantially impair sleep quality, daily functioning, emotional well-being, and overall quality of life.
Management strategies include lifestyle modifications, non-prescription remedies, hormonal therapies, and non-hormonal prescription medications, with treatment selection depending on symptom severity, patient preference, and individual risk factors. The introduction of targeted non-hormonal therapies has significantly expanded therapeutic options for women who are not candidates for hormone replacement therapy.

Vasomotor Symptoms Epidemiology Segmentation

The DelveInsight report provides a comprehensive epidemiological assessment of Vasomotor Symptoms across the 7MM and ROW during 2020-2036, segmented into:
• Total Prevalent Cases of Vasomotor Symptoms
• Total Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Severity-specific Diagnosed Prevalent Cases (Mild, Moderate, and Severe)
• Total Treatable Cases
• Country-specific Epidemiology across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and the Rest of the World (ROW)

Download the report to explore detailed epidemiology trends, marketed and emerging therapies, and future commercial opportunities in the Vasomotor Symptoms market:
https://www.delveinsight.com/sample-request/vasomotor-symptoms-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Vasomotor Symptoms Market Report

• Study Period: 2020-2036
• Coverage: Seven Major Markets (7MM) + Rest of the World (ROW) [United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and ROW]
• Key Companies: Pfizer, Astellas Pharma, Bayer, Noema Pharma, Tioga Pharmaceuticals, Changchun GeneScience Pharmaceuticals, and other emerging companies developing therapies for vasomotor symptoms.
• Marketed Therapies: DUAVEE (bazedoxifene acetate/conjugated estrogens), VEOZAH (fezolinetant), LYNKUET (elinzanetant), hormone replacement therapies (HRT), and other supportive treatment options.
• Emerging Therapies: Cendifensine (NOE-115), Asimadoline, GenSci074, and other investigational non-hormonal therapies.
• Epidemiology Segmentation: Total prevalent cases, diagnosed prevalent cases, age-specific diagnosed cases, severity-specific diagnosed cases, total treatable cases, and country-specific epidemiology across the 7MM + ROW.
• Market Insights: Historical and forecasted market size, therapy uptake, pricing trends, analogue assessment, competitive landscape, SWOT analysis, unmet needs, and market forecasts through 2036.
• Market Access: Country-specific reimbursement and Health Technology Assessment (HTA) landscape across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
• Additional Coverage: Patient journey, Key Opinion Leader (KOL) insights, therapy launch analysis, market access, rebates, and analyst perspectives.

To learn more about the Vasomotor Symptoms market, emerging therapies, and future commercial opportunities, visit:
https://www.delveinsight.com/sample-request/vasomotor-symptoms-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• Vasomotor Symptoms Market Report Introduction
• Vasomotor Symptoms Market Executive Summary
• Vasomotor Symptoms Market Overview
• Vasomotor Symptoms Epidemiology Analysis
• Vasomotor Symptoms Patient Journey
• Vasomotor Symptoms Treatment Landscape
• Marketed Therapies
• Emerging Therapies
• Vasomotor Symptoms Market Dynamics
• Vasomotor Symptoms Market Size and Forecast (2020-2036)
• Competitive Landscape
• Key Companies
• Key Marketed Therapies
• Key Emerging Therapies
• Epidemiology Segmentation
• Pricing Trends and Analogue Analysis
• Market Access and Reimbursement
• Key Opinion Leaders' Views
• SWOT Analysis
• Unmet Needs
• Market Drivers and Barriers
• Future Perspectives
• Analyst Views
• Appendix

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.